Previous 10 | Next 10 |
home / stock / btai / btai articles
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ:IBRX) Lifshitz Law PLLC announces investigation into possible securities...
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Baxter International, Inc. (NYSE:BAX) Johnson Fistel, LLP is investigating potential claims on be...
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or th...
RADNOR, Pa., Sept. 04, 2023 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a s...
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Arrow Financial Corp. (NASDAQ:AROW) Lifshitz Law PLLC announces investigation into possible securi...
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXce...
NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders ...
BENSALEM, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on ...
LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 5, 2023 dead...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...